CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 90 enrolled
Drug / intervention
SBP-9330 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04948827
NCT04948827Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects

Camino Pharma, LLC·interventional·Posted Jul 2, 2021·Updated Apr 16, 2024

In Brief

A Phase 1 clinical trial evaluating SBP-9330 and Placebo for Smoking Cessation. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Sanford Burnham Prebys, University of California, San Diego

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJul 2, 2021
Enrollment StartJul 20, 2021
Primary CompletionMar 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5 years ago

Interventions

SBP-9330drug

SBP-9330 oral capsules

Placebodrug

Placebo oral capsules